Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Current Liabilities (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Total Current Liabilities for 14 consecutive years, with $92.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities changed 0.22% year-over-year to $92.1 million, compared with a TTM value of $92.1 million through Dec 2025, changed 0.22%, and an annual FY2025 reading of $92.1 million, changed 0.22% over the prior year.
  • Total Current Liabilities was $92.1 million for Q4 2025 at Karyopharm Therapeutics, up from $87.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $99.2 million in Q2 2025 and bottomed at $57.6 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $70.8 million, with a median of $65.6 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities dropped 10.59% in 2022, then soared 72.19% in 2025.
  • Year by year, Total Current Liabilities stood at $73.7 million in 2021, then decreased by 10.59% to $65.9 million in 2022, then grew by 5.42% to $69.5 million in 2023, then surged by 32.79% to $92.3 million in 2024, then fell by 0.22% to $92.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for KPTI at $92.1 million in Q4 2025, $87.2 million in Q3 2025, and $99.2 million in Q2 2025.